Association of Gonadotropin-Releasing Hormone Therapies With Venous Thromboembolic Events in Patients With Prostate Cancer: A National Cohort Study

被引:3
作者
Hong, Chon-Seng [1 ]
Chen, Yi-Chen [2 ]
Ho, Chung-Han [2 ,3 ]
Hsieh, Kun-Lin [4 ,5 ]
Chen, Michael [1 ]
Shih, Jhih-Yuan [1 ,6 ]
Chiang, Chun-Yen [1 ,7 ]
Chen, Zhih-Cherng [1 ]
Chang, Wei-Ting [1 ,8 ,9 ]
机构
[1] Chi Mei Med Ctr, Div Cardiol, Dept Internal Med, Tainan, Taiwan
[2] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan
[3] Southern Taiwan Univ Sci & Technol, Dept Informat Management, Tainan, Taiwan
[4] Chi Mei Med Ctr, Div Urol, Dept Surg, Tainan, Taiwan
[5] Natl Cheng Kung Univ, Dept Environm & Occupat Hlth, Coll Med, Tainan, Taiwan
[6] Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr, Tainan, Taiwan
[7] Chung Hwa Univ Med Technol, Dept Optometry, Tainan, Taiwan
[8] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan
[9] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 9卷
关键词
prostate cancer; GnRH therapies; androgen deprivation therapies; venous thromboembolic events; age; cancer stage; ANDROGEN-DEPRIVATION THERAPY; RISK; EPIDEMIOLOGY; THROMBOSIS; AGONISTS; DISEASE; STATINS; TAIWAN; STROKE; MEN;
D O I
10.3389/fcvm.2022.794310
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although androgen deprivation therapy (ADT) has been proposed to be associated with a higher risk of venous thromboembolisms (VTEs), whether gonadotropin-releasing hormones (GnRHs), such as both agonists and antagonists, are also associated with VTEs remain unclear. Using the Taiwan Cancer Registry (TCR) linked with the National Health Insurance Research Database, we identified patients diagnosed with prostate cancer from 2008 to 2015. Patients who received GnRH were 1:1 propensity score matched with non-GnRH users by age and cancer stage at diagnosis and clinical stage. Cox regression analysis was applied to estimate the incidences of VTEs with death as a competing event at the 5-year follow-up. The VTE incidence among GnRH users was 1.13% compared with 0.98% among non-users. After adjusting with potential confounding factors, the risk of VTEs showed borderline statistical significance among GnRH users and non-users. Notably, in the subgroup analysis among patients receiving GnRH therapy, those younger than 70 years old or at an earlier stage (stage I/II) were at a higher risk of VTEs. Different from previous studies, our findings highlighted critical concerns regarding the cardiac safety of GnRH therapies in prostate cancer patients at a relatively younger age or at an earlier stage.
引用
收藏
页数:8
相关论文
共 40 条
[21]   Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review [J].
Meng, Fanzheng ;
Zhu, Shimiao ;
Zhao, Jinsheng ;
Vados, Larissa ;
Wang, Lei ;
Zhao, Yusheng ;
Zhao, Dan ;
Niu, Yuanjie .
BMC CANCER, 2016, 16
[22]   Prostate Cancer, Version 2.2019 [J].
Mohler, James L. ;
Antonarakis, Emmanuel S. ;
Armstrong, Andrew J. ;
D'Amico, Anthony, V ;
Davis, Brian J. ;
Dorff, Tanya ;
Eastham, James A. ;
Enke, Charles A. ;
Farrington, Thomas A. ;
Higano, Celestia S. ;
Horwitz, Eric Mark ;
Hurwitz, Michael ;
Ippolito, Joseph E. ;
Kane, Christopher J. ;
Kuettel, Michael R. ;
Lang, Joshua M. ;
McKenney, Jesse ;
Netto, George ;
Penson, David F. ;
Plimack, Elizabeth R. ;
Pow-Sang, Julio M. ;
Pugh, Thomas J. ;
Richey, Sylvia ;
Roach, Mack, III ;
Rosenfeld, Stan ;
Schaeffer, Edward ;
Shabsigh, Ahmad ;
Small, Eric J. ;
Spratt, Daniel E. ;
Srinivas, Sandy ;
Tward, Jonathan ;
Shead, Dorothy A. ;
Freedman-Cass, Deborah A. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (05) :479-505
[23]   Landmark analysis: A primer [J].
Morgan, Charity J. .
JOURNAL OF NUCLEAR CARDIOLOGY, 2019, 26 (02) :391-393
[24]   Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Parker, C. ;
Castro, E. ;
Fizazi, K. ;
Heidenreich, A. ;
Ost, P. ;
Procopio, G. ;
Tombal, B. ;
Gillessen, S. .
ANNALS OF ONCOLOGY, 2020, 31 (09) :1119-1134
[25]   Epidemiology of Prostate Cancer [J].
Rawla, Prashanth .
WORLD JOURNAL OF ONCOLOGY, 2019, 10 (02) :63-89
[26]   Use of statins and the subsequent development of deep vein thrombosis [J].
Ray, JG ;
Mamdani, M ;
Tsuyuki, RT ;
Anderson, DR ;
Yeo, EL ;
Laupacis, A .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (11) :1405-1410
[27]   Statins, inflammation and deep vein thrombosis: a systematic review [J].
Rodriguez, April L. ;
Wojcik, Brandon M. ;
Wrobleski, Shirley K. ;
Myers, Daniel D., Jr. ;
Wakefield, Thomas W. ;
Diaz, Jose A. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2012, 33 (04) :371-382
[28]   The role of the androgen receptor in prostate cancer-induced platelet aggregation and platelet-induced invasion [J].
Rudzinski, Jan K. ;
Govindasamy, Natasha P. ;
Lewis, John D. ;
Jurasz, Paul .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (11) :2976-2986
[29]   Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy [J].
Secin, Fernando P. ;
Jiborn, Thomas ;
Bjartell, Anders S. ;
Fournier, Georges ;
Salomon, Laurent ;
Abbou, Clement Claude ;
Haber, George P. ;
Gill, Inderbir S. ;
Crocitto, Laura E. ;
Nelson, Rebecca A. ;
Alcaide, Jose R. Cansino ;
Martinez-Pineiro, Luis ;
Cohen, Michael S. ;
Tuerk, Ingolf ;
Schulman, Claude ;
Gianduzzo, Troy ;
Eden, Christopher ;
Baumgartner, Roxelyn ;
Smith, Joseph A. ;
Entezari, Kim ;
van Velthouen, Roland ;
Janetschek, Gunter ;
Serio, Angel M. ;
Vickers, Andrew J. ;
Touijer, Karim ;
Guillonneau, Bertrand .
EUROPEAN UROLOGY, 2008, 53 (01) :134-145
[30]   Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis [J].
Seidenfeld, J ;
Samson, DJ ;
Hasselblad, V ;
Aronson, N ;
Albertsen, PC ;
Bennett, CL ;
Wilt, TJ .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (07) :566-577